RE-BVS – Piemonte Repository

Sfoglia per AUTORE
ZUCALI P
Collezione AOU Alessandria

Items : 11

Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication. in Journal of immunotherapy (Hagerstown, Md. : 1997) / J Immunother. 2023 Jan 1;46(1):22-26. doi: 10.1097/CJI.0000000000000446. Epub 2022 Nov 4.

2023
AOU Alessandria

Masini C; Chini C; Zai S; Nole' F; Mirabelli R; Hamzaj A; Favaretto A; Leo S; Baldini E; Zafarana E; Aschele C; Zucali PA; Cusmai A; Sabbatini R; Santoni M; Lo Re G; Fonarini G; Procopio G; Carrozza F; Porta C; Galli L; Iacovelli R; Maruzzo M; De Giorgi U; Giannarelli D; Buti S; Basso U; Fatigoni S; Rocchi A; et alii...

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. in Lancet (London, England) / Lancet. 2023 Dec 16;402(10419):2295-2306. doi: 10.1016/S0140-6736(23)01613-6. Epub 2023 Nov 3.

2023
AOU Alessandria

Chu Q; Perrone F; Greillier L; Tu W; Piccirillo MC; Grosso F; Lo Russo G; Florescu M; Mencoboni M; Morabito A; Cecere FL; Ceresoli GL; Dawe DE; Zucali PA; Pagano M; Goffin JR; Sanchez ML; Gridelli C; Zalcman G; Quantin X; Westeel V; Gargiulo P; Delfanti S; Tu D; Lee CW; Leighl N; Sederias J; Brown-Walker P; Luo Y; et alii...

Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study. in International journal of molecular sciences / Int J Mol Sci. 2022 May 21;23(10):5786. doi: 10.3390/ijms23105786.

2022
AOU Alessandria
ASL Alessandria

Ceresoli GL; Marchini S; Allavena P; Zucali PA; Muzio A; Delfanti S; De Angelis A; Libener R; Penpa S; Callari M; Inglesi A; Amodeo R; Lupi M; Bosetti C; Vedovelli L; De Simone I; Moracci L; Olteanu GE; Pezzuto F; Paracchini L; Mannarino L; Calabrese F; D'Incalci M; Grosso F;

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study. in ESMO open / ESMO Open. 2022 Jun;7(3):100446. doi: 10.1016/j.esmoop.2022.100446. Epub 2022 Apr 12.

2022
AOU Alessandria

Mark M; Rusakiewicz S; Früh M; Hayoz S; Grosso F; Pless M; Zucali P; Ceresoli GL; Maconi A; Schneider M; Froesch P; Tarussio D; Benedetti F; Dagher J; Kandalaft L; von Moos R; Tissot-Renaud S; Schmid S; Metaxas Y;

Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations. in Cell death & disease / Cell Death Dis. 2022 Jul 15;13(7):612. doi: 10.1038/s41419-022-05073-4.

2022
AOU Alessandria

Mannarino L; Mirimao F; Panini N; Paracchini L; Marchini S; Beltrame L; Amodeo R; Grosso F; Libener R; De Simone I; Ceresoli GL; Zucali PA; Lupi M; D'Incalci M;

Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma. in ESMO open / ESMO Open. 2022 Dec;7(6):100644. doi: 10.1016/j.esmoop.2022.100644. Epub 2022 Dec 1.

2022
AOU Alessandria

Canova S; Ceresoli GL; Grosso F; Zucali PA; Gelsomino F; Pasello G; Mencoboni M; Rulli E; Galli F; De Simone I; Carlucci L; De Angelis A; Belletti M; Bonomi M; D'Aveni A; Perrino M; Bono F; Cortinovis DL;

Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Oct;22(10):1438-1447. doi: 10.1016/S1470-2045(21)00404-6. Epub 2021 Sep 6.

2021
AOU Alessandria

Pinto C; Zucali PA; Pagano M; Grosso F; Pasello G; Garassino MC; Tiseo M; Soto Parra H; Grossi F; Cappuzzo F; de Marinis F; Pedrazzoli P; Bonomi M; Gianoncelli L; Perrino M; Santoro A; Zanelli F; Bonelli C; Maconi A; Frega S; Gervasi E; Boni L; Ceresoli GL;

Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study. in Clinical lung cancer / Clin Lung Cancer. 2021 Jul;22(4):361-370.e3. doi: 10.1016/j.cllc.2020.06.028. Epub 2020 Jul 3.

2021
AOU Alessandria

Maconi A; Canova S; Rulli E; Torri V; Galli F; Hollander L; Sperandi F; Tiseo M; Pasello G; Zucali PA; Carlucci L; Grosso F; Cortinovis D; Bidoli P; Ceresoli GL; D'Incalci M;

Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. in Cancers / Cancers (Basel). 2020 Oct 13;12(10):2948. doi: 10.3390/cancers12102948.

2020
AOU Alessandria

Pagano M; Ceresoli LG; Zucali PA; Pasello G; Garassino M; Grosso F; Tiseo M; Soto Parra H; Zanelli F; Cappuzzo F; Grossi F; De Marinis F; Pedrazzoli P; Gnoni R; Bonelli C; Torricelli F; Ciarrocchi A; Normanno N; Pinto C;

Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2020 Nov;140:140-146. doi: 10.1016/j.ejca.2020.09.018. Epub 2020 Oct 20.

2020
AOU Alessandria

Caffo O; Gasparro D; Di Lorenzo G; Volta AD; Guglielmini P; Zucali P; Bortolus R; Cavo A; Ceresoli G; Chiari R; Fornarini G; Fratino L; Iaculli A; Maruzzo M; Masini C; Morelli F; Mucciarini C; Procopio G; Sabbatini R; Verri E; Kinspergher S; Maines F; Messina C; Veccia A; Donini M;

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16). in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2020 Apr;31(4):495-500. doi: 10.1016/j.annonc.2019.12.009. Epub 2020 Jan 16.

2020
AOU Alessandria

Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;